STRATEC SE Annual Meeting: Dividend Approved, All Resolutions Passed

At today's Annual General Meeting, shareholders of STRATEC SE (Frankfurt: SBS; Prime Standard) gave overwhelming approval to all proposed resolutions, marking a strong vote of confidence in the company's leadership and strategy. The key outcome was the approval of a dividend of EUR 0.60 per share for the 2024 financial year, matching the previous year's dividend, with total distribution reaching EUR 7.3 million. This dividend will be paid to shareholders via their depositing banks on June 26, 2026. Additionally, shareholders endorsed the actions of the Board of Management and the Supervisory Board, elected PricewaterhouseCoopers GmbH Wirtschaftsprüfungs-gesellschaft (PwC) as auditor for the 2026 financial year, and approved the remuneration report. The Annual General Meeting saw a strong turnout, with 70.1 percent of the company's registered share capital represented. For more details, including voting results, visit www.stratec.com/agm.

STRATEC SE, headquartered in Birkenfeld, Germany, is a leading partner in the design and manufacture of fully automated analyzer systems for clinical diagnostics and life sciences. The company also produces complex consumables for diagnostic and medical applications, covering the entire value chain from development to quality assurance. Its partners market these systems, software, and consumables, often paired with their own reagents, as complete solutions to laboratories, blood banks, and research institutes worldwide. STRATEC's innovative products are built on patented technologies, and its shares are traded in the Prime Standard segment of the Frankfurt Stock Exchange. Notably, the company's commitment to shareholder returns, evidenced by the consistent dividend, underscores its stability and growth prospects. For more information about STRATEC and its offerings, visit www.stratec.com.

The meeting also highlighted STRATEC's strong governance and transparency, with the appointment of PwC as auditor for 2026 and approval of the remuneration report. This Annual General Meeting reinforces STRATEC's dedication to aligning with shareholder interests and maintaining robust corporate governance. The high shareholder representation and unanimous approval of all agenda items signal confidence in the company's direction and operational performance. As STRATEC continues to innovate in the diagnostics and life sciences sectors, its focus on shareholder value remains a cornerstone of its corporate strategy. The original release can be viewed on www.newmediawire.com.